Clinical Trial Update: Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) [Phase 3]

View source ↗

Summary

Phase 3 LASER301 trial evaluating Lazertinib as first-line treatment for EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Yuhan Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-22